Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2023）

引用 4|浏览51

暂无评分

摘要

Camrelizumab plus carboplatin and pemetrexed provides long-term survival benefit over chemotherapy, with manageable toxicity and remarkable and durable response in patients receiving 2 years of camrelizumab, further supporting camrelizumab combination as first-line treatment for advanced nonsquamous NSCLC.

查看译文

关键词

Camrelizumab,Chemotherapy,Immunotherapy,Nonsquamous non–small cell lung cancer,PD-1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要